Assessing Potential Implications of New Data on CMV Treatment in Transplant Recipients

Program Overview

The management of cytomegalovirus (CMV) infection or disease in transplant patients has historically been challenging due to side effects with older antiviral therapies, including myelotoxicity and renal toxicity. Side effect and efficacy data for newer improved transplant antiviral therapies, including maribavir and letermovir, is emerging rapidly. The goal of this activity is to help you learn about the emerging data and how to apply it in clinical practice when managing your transplant patients.

Credit Expired

Target Audience

Infectious disease, nephrology, and transplantation clinicians and pharmacists who provide care for transplant patients with cytomegalovirus (CMV) infection.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Employ late-breaking data on the efficacy of available antiviral therapies when managing cytomegalovirus (CMV) in solid organ transplant (SOT) patients
  • Utilize new data on the safety and tolerability of available antiviral therapies for CMV management in the SOT setting

Activity Faculty

Camille Kotton portrait 2021

Camille Nelson Kotton, MD, FIDSA, FAST

Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts, United States


Atul Humar, MD, MSc, FRCPC, FAST

Professor, Department of Medicine
University of Toronto
R. Fraser Elliott Chair, Transplantation
University Health Network
Director, University of Toronto Transplant Institute
Toronto, Ontario, Canada



Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources